Cargando…

Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review

Most conventional insomnia medications are gamma‐aminobutylic acid receptor agonists. However, physical dependence is a concern and one of the major limiting factors for long‐term treatment. The dual orexin receptor antagonists, suvorexant and lemborexant, were recently approved for treating chronic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kishi, Taro, Nishida, Maika, Koebis, Michinori, Taninaga, Takehiro, Muramoto, Kenzo, Kubota, Naoki, Moline, Margaret, Sakuma, Kenji, Okuya, Makoto, Nomura, Ikuo, Iwata, Nakao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698673/ https://www.ncbi.nlm.nih.gov/pubmed/34553844 http://dx.doi.org/10.1002/npr2.12205

Ejemplares similares

Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
por: Kishi, Taro, et al.
Publicado: (2019)

Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2021)

Orexin receptor antagonists as therapeutic agents for insomnia
por: Equihua, Ana C., et al.
Publicado: (2013)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020)

Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020)

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
por: Kishi, Taro, et al.
Publicado: (2021)

Body composition in Japanese patients with psychiatric disorders: A cross‐sectional study
por: Kishi, Taro, et al.
Publicado: (2021)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Melatonin receptor agonists—ramelteon and melatonin—for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2019)

Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2019)

The clinical efficacy of orexin antagonists for primary insomnia- A review of the evidence
por: Vasiliu, O.
Publicado: (2023)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2015)

Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2020)

Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression
por: Kishi, Taro, et al.
Publicado: (2022)

Prevalence of and factors associated with acute withdrawal symptoms after 24 weeks of eszopiclone treatment in patients with chronic insomnia: a prospective, interventional study
por: Inoue, Yuichi, et al.
Publicado: (2021)

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman, Jessica L, et al.
Publicado: (2016)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023)

Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis
por: Rocha, Rebeka Bustamante, et al.
Publicado: (2023)

Orexin Receptor Competitive Antagonists: A Novel target of the Sedative and hypnotics drugs for the pharmacotherapy of Insomnia
por: Banerjee, Indrajit
Publicado: (2018)

Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis
por: Xue, Tao, et al.
Publicado: (2023)

Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review
por: Besterman, Aaron D., et al.
Publicado: (2021)

Efficacy and safety of lemborexant in midlife women with insomnia disorder
por: Terauchi, Masakazu, et al.
Publicado: (2023)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Effect of Psychoeducational Intervention on Donepezil Retention Rate and Analysis of Reasons for the Discontinuation in Patients with Alzheimer’s Dementia: A Randomized Study
por: Kamei, Tetsumasa, et al.
Publicado: (2021)

A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
por: Ziemichód, Wojciech, et al.
Publicado: (2022)

Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta‐analysis of double‐blind, randomized, placebo‐controlled trials with an enrichment design
por: Oya, Kazuto, et al.
Publicado: (2019)

The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
por: Moline, Margaret, et al.
Publicado: (2023)

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System
por: Fragale, Jennifer E., et al.
Publicado: (2021)

Factors Associated with Prescriptions for an Orexin Receptor Antagonist Among Japanese Patients with Insomnia: Analysis of a Nationwide Japanese Claims Database
por: Okuda, Shoki, et al.
Publicado: (2023)

Opportunities and perspectives for developing orexin receptor antagonists
por: Steiner, Michel A., et al.
Publicado: (2014)

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
por: Yeoh, Jiann Wei, et al.
Publicado: (2014)

Efficient marmoset genome engineering by autologous embryo transfer and CRISPR/Cas9 technology
por: Abe, Yukiko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jcm3gf64hchmme1qvjm1fjjlun